Patents by Inventor Jeanmarie Guenot

Jeanmarie Guenot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS
    Publication number: 20240084009
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: March 22, 2023
    Publication date: March 14, 2024
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan LEMON
  • SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
    Publication number: 20230257451
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: September 19, 2022
    Publication date: August 17, 2023
    Inventors: Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT
  • Single chain variable fragment CD3 binding proteins
    Patent number: 11623958
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: April 11, 2023
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan Lemon
  • Single domain serum albumin binding protein
    Patent number: 11453716
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: September 27, 2022
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Luke Evnin, Jeanmarie Guenot
  • CD33×CD3 BINDING PROTEINS FOR TREATING INFLAMMATORY CONDITIONS AND DISEASES
    Publication number: 20210324076
    Abstract: Described herein are bispecific binding proteins that specifically bind to an antigen expressed on a target cell and an antigen expressed on a T-cell, e.g., human CD33 and human CD3 and therapeutically effective dosing regimens for the treatment and amelioration of an inflammatory disease and condition.
    Type: Application
    Filed: October 11, 2019
    Publication date: October 21, 2021
    Inventors: Jeanmarie Guenot, Eric Feldman, Tae Han
  • TRISPECIFIC BINDING PROTEINS AND METHODS OF USE
    Publication number: 20210179735
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 17, 2021
    Inventors: Patrick BAEUERLE, Luke EVNIN, Jeanmarie GUENOT, Vanitha RAMAKRISHNAN, Holger WESCHE
  • PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
    Publication number: 20210100902
    Abstract: Disclosed are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed and methods of using such formulations are further provided.
    Type: Application
    Filed: September 23, 2020
    Publication date: April 8, 2021
    Inventors: Robert DUBRIDGE, Pui SETO, Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
  • PSMA Targeting Trispecific Proteins and Methods of Use
    Publication number: 20210095047
    Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 1, 2021
    Inventors: Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Pui SETO
  • Trispecific binding proteins and methods of use
    Patent number: 10954311
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: March 23, 2021
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Patrick Baeuerle, Luke Evnin, Jeanmarie Guenot, Vanitha Ramakrishnan, Holger Wesche
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20210024654
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: March 18, 2020
    Publication date: January 28, 2021
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Prostate specific membrane antigen binding protein
    Patent number: 10849973
    Abstract: Disclosed herein are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 1, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert Dubridge, Pui Seto, Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Bryan D. Lemon, Richard J. Austin
  • PSMA targeting trispecific proteins and methods of use
    Patent number: 10844134
    Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: November 24, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Pui Seto
  • DOSING REGIMEN FOR CD3 BINDING PROTEINS
    Publication number: 20200262920
    Abstract: Described herein are bispecific binding proteins that specifically bind to an antigen expressed on a target cell and an antigen expressed on a T-cell, e.g., human CD33 and human CD3 and therapeutically effective dosing regimens for immunotherapy of cancers, diseases and conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and solid tumor cancers.
    Type: Application
    Filed: October 12, 2018
    Publication date: August 20, 2020
    Inventors: Jeanmarie Guenot, Eric Feldman, Tae Han
  • Methods of using bispecific CD33 and CD3 binding proteins
    Patent number: 10738118
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 11, 2020
    Assignee: Amphivena Therapeutics, Inc.
    Inventors: Luke Evnin, Jeanmarie Guenot, Lori Kunkel
  • SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS
    Publication number: 20200231672
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: January 27, 2020
    Publication date: July 23, 2020
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan LEMON
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 10626190
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Amphivena Therapeutics, Inc.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Single chain variable fragment CD3 binding proteins
    Patent number: 10544221
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 28, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan D. Lemon
  • INNATE IMMUNE CELL TRISPECIFIC BINDING PROTEINS AND METHODS OF USE
    Publication number: 20190225702
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to innate immune cells, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: October 13, 2017
    Publication date: July 25, 2019
    Inventors: Patrick BAEUERLE, Luke EVNIN, Jeanmarie GUENOT, Holger WESCHE
  • SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
    Publication number: 20190031749
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: October 16, 2018
    Publication date: January 31, 2019
    Inventors: Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT
  • Single domain serum albumin binding protein
    Patent number: 10100106
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: October 16, 2018
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Luke Evnin, Jeanmarie Guenot